Related Experiment Video
Updated: May 17, 2026
07:58
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
Using a pharmacogenomic algorithm to guide the treatment of depression
D K Hall-Flavin1, J G Winner, J D Allen
1Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA. flavin.daniel@mayo.edu
Translational Psychiatry
|October 11, 2012
Summary
Pharmacogenomic testing reports significantly improved psychotropic medication selection and dosing for depressed patients. Guided treatment led to greater symptom reduction compared to unguided care in an outpatient psychiatric setting.
Area of Science:
- Psychiatry
- Pharmacogenomics
- Clinical Psychology
Background:
- Psychotropic medication management is complex.
- Individual variability in drug response necessitates personalized treatment approaches.
- Pharmacogenomic testing offers potential to optimize medication selection and dosing.
Purpose of the Study:
- To assess the clinical utility of pharmacogenomic testing reports in guiding psychotropic medication management.
- To compare treatment outcomes in depressed patients receiving pharmacogenomic-guided versus unguided care.
- To evaluate patient and clinician satisfaction with pharmacogenomic-guided treatment.
Main Methods:
- A prospective, non-randomized, open-label cohort study.
- Two groups of depressed outpatients: pharmacogenomic-guided (n=?) and unguided (n=?).
- Depression severity assessed using QIDS-C16 and HAM-D17 scales over 8 weeks.
Main Results:
- The pharmacogenomic-guided group showed significantly greater reduction in depressive symptoms (QIDS-C16: P=0.002; HAM-D17: P=0.04).
- Improved clinical outcomes were observed in patients receiving pharmacogenomic-guided treatment.
- Higher patient and clinician satisfaction was noted in the guided group (data not shown).
Conclusions:
- Rapidly available pharmacogenomic interpretive reports can provide valuable clinical guidance.
- Pharmacogenomic testing is associated with improved treatment outcomes for depression in outpatient psychiatric settings.
- Personalized pharmacogenomic approaches enhance psychotropic medication management.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...